HCC associated long non-coding RNA (HANR) (HANR)

HCC associated long non-coding RNA (HANR), also known as RPL13AP20 (Ribosomal protein L13a pseudogene 20), is a long non-coding RNA (lncRNA) that does not encode a protein but regulates various cellular functions, particularly in the context of cancer. HANR is overexpressed in several malignancies, including hepatocellular carcinoma (HCC) and colorectal cancer, where it contributes to enhanced tumor cell proliferation, invasion, and epithelial-mesenchymal transition (EMT)[3]. Multiple studies have shown its role as a prognostic biomarker for advanced disease and poor outcome[3]. As an lncRNA and pseudogene, it does not possess conventional receptor, enzyme, or transporter activity, and there are currently no approved drugs or direct therapeutic strategies targeting HANR. Its classification as a "ribosomal protein pseudogene" is historical and based on sequence homology, rather than any direct involvement in ribosomal structure or function[2]. The molecule is currently of research interest due to its regulatory functions in cancer biology but is not recognized as a direct therapeutic target. No drugs are documented to interact with HANR/RPL13AP20 directly, nor does the literature describe classic mechanisms of therapeutic modulation for this lncRNA[2][3][6]. Its disease associations are through biomarker and gene regulation studies, not direct drug targeting.

Other names

RPL13AP20Ribosomal protein L13a pseudogene 20hCG_27695RPL13A_9_1211HCC-associated long non-coding RNA